Gordon Guyatt's Confession: What the Father of Evidence-Based Medicine Didn't Read (#36)
8 September 2025
With Gordon Guyatt
Global
Gordon Guyatt coined the term 'evidence-based medicine' in 1991 and developed the evidentiary frameworks that govern clinical decision-making worldwide. His systematic reviews found only low-quality evidence for youth gender interventions — conclusions that mirror those of the Cass Review in England. Yet he objected when governments acted on those findings, and admits signing an advocacy statement endorsing gender treatments for minors without reading it. The episode examines the gap between rigorous scientific method and the political commitments scientists sometimes make outside it, with direct consequences for UK children's gender policy.
Gordon Guyatt is one of the most consequential figures in modern medicine. As a professor at McMaster University in Canada, he coined the phrase 'evidence-based medicine' in 1991 and developed the hierarchy of evidence that underpins how physicians worldwide are trained to evaluate clinical research. His systematic reviews carry authority precisely because he designed the instruments used to assess them. That authority is at the centre of this episode. When Guyatt's team applied their own methodology to paediatric gender medicine, they concluded that the evidence base for youth interventions was of low quality. That finding aligns closely with the conclusions of the Cass Review, the independent examination of NHS gender services in England published in April 2024, which found the evidence for puberty blockers and cross-sex hormones in under-eighteens insufficient to justify routine clinical use. NHS England subsequently withdrew both treatments from routine commissioning. In both cases — McMaster's systematic reviews and the Cass Review — the same evidentiary standard produced the same result. What makes this interview striking is that Guyatt simultaneously objected to governments using his findings to restrict access to gender treatments, describing such use as egregious and unconscionable. The hosts then confront him with his own signature on a statement endorsing medically necessary care for gender-diverse youth. He admits he did not read the statement carefully before signing it and acknowledges that the relevant passage was not one he had drafted. His admission that he was, in his own words, 'a dope' is not incidental: it illustrates precisely how advocacy and scientific credentialing can blur at the point where they should be most carefully separated. The question of adolescent informed consent receives sustained attention. Asked whether young people can genuinely consent to interventions affecting future fertility, Guyatt defers to clinicians who support the treatments while insisting he is a total non-expert in the area. That combination — lending his name to policy advocacy while disavowing expertise in the underlying clinical questions — is the tension the hosts press throughout the conversation. In England, the legal framework around Gillick competence for minors has already been tested in gender medicine litigation, and the question of whether young people can meaningfully weigh long-term consequences remains unsettled in courts as well as clinics. Guyatt is also challenged on a historical parallel: the campaign in the 1990s for bone marrow transplants as a breast cancer treatment. Activists at the time argued that withholding access was unconscionable; randomised trials later demonstrated the treatment was ineffective and caused serious harm. The same rhetorical structure — urgency, patient autonomy, the cruelty of delay — appears in the current debate over youth gender medicine. When pressed on this, Guyatt responds that he feels manipulated, which sidesteps the analytical question the parallel raises about how medical consensus can harden prematurely under social pressure. For those following the post-Cass landscape in Britain, this episode provides essential context. It shows the degree to which advocacy became entangled with the scientific infrastructure that ought to remain independent of it. When the architect of the tools for evaluating medical evidence concedes that he signed statements without reading them, it raises serious questions about the integrity of the consensus that was used, for over a decade, to resist reform of children's gender services on both sides of the Atlantic.
